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Abstract – Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health burden in
Latin America and a potentially serious emerging threat to a number of countries throughout the world. Although pub-
lic health programs have signiﬁcantly reduced the prevalence of Chagas disease in Latin America in recent decades, the
number of infections in the United States and non-endemic countries in Europe and the Western Paciﬁc Region con-
tinues to rise. Moreover, there is still no vaccine or highly effective cure available for the approximately 10 million
people currently infected with T. cruzi, a third of which will develop potentially fatal cardiomyopathy and/or severe
digestive tract disorders. As Chagas disease becomes an increasingly globalized public health issue in the twenty-ﬁrst
century, continued attentiveness from governmental and health organizations as well as improved diagnostic tools, ex-
panded surveillance and increased research funding will be required to maintain existing public health successes and
stymie the spread of the disease to new areas and populations.
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Re´sume´ – La maladie de Chagas au XXIe sie`cle : un succe`s de sante´ publique ou une menace e´mergente ? La
maladie de Chagas, cause´e par le protozoaire parasite Trypanosoma cruzi, est un proble`me de sante´ publique majeur en
Ame´rique latine et une menace e´mergente potentiellement grave dans un certain nombre de pays a` travers le monde.
Bien que les programmes de sante´ publique aient conside´rablement re´duit la pre´valence de la maladie de Chagas en
Ame´rique latine au cours des dernie`res de´cennies, le nombre d’infections aux E´tats-Unis et les pays non-
ende´miques d’Europe et de la Re´gion du Paciﬁque occidental continue d’augmenter. En outre, il n’existe encore
aucun vaccin ou reme`de tre`s efﬁcace disponible pour les quelque 10 millions de personnes actuellement infecte´es
par T. cruzi, dont un tiers va de´velopper une cardiomyopathie potentiellement mortelle et / ou des troubles digestifs
se´ve`res. Comme la maladie de Chagas devient un proble`me de plus en plus globalise´ de sante´ publique au XXIe
sie`cle, une attention continue des organisations gouvernementales et de sante´ ainsi que des outils de diagnostic
ame´liore´s, une surveillance accrue et un ﬁnancement accru de la recherche seront ne´cessaires pour maintenir les
bons re´sultats actuels de sante´ publique et entraver la propagation de la maladie a` de nouvelles re´gions et populations.
Introduction
Chagas disease (Human American Trypanosomiasis) was
ﬁrst described in 1909 when Carlos Chagas identiﬁed the pro-
tozoan parasite Trypanosoma cruzi as the cause of an acute feb-
rile illness afﬂicting Brazilian railroad workers [84]. It is likely
that the insect vectors that spread T. cruzi had been transmitting
the parasite among wild animals in Central and South America
for millions of years before the disease crossed over into
domestic animals and humans more than 9000 years
ago [7, 26]. Approximately 200–300 years ago, as rapid conver-
sion of the natural forest habitat of the vector into farmland cre-
ated myriad opportunities for T. cruzi to spread to domesticated
animals, Chagas disease became an endemic zoonosis [28].
Urbanization of rural populations in the mid-twentieth century,
which involved the migration of large numbers of infected indi-
viduals to areas with a comparatively low risk of vectorial trans-
mission, extended the endemic to cities. However, the disease
has remained largely conﬁned to poor rural areas. By the end
of the twentieth century, Chagas disease had become widely
recognized by the World Health Organization (WHO) and other
public health authorities as a neglected tropical disease because
it primarily affects low-income populations, is a major cause of
chronic morbidity and mortality in developing tropical
countries, and has been historically underrepresented in the
allocation of health-promoting resources from research, govern-
mental, and public aid organizations. Chagas disease is a*Corresponding author: kevin.bonney@kbcc.cuny.edu
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serious public health burden in Latin America (Table 1), costing
the region an estimated 662,000 disability-adjusted life-years
(DALYs) of productivity as of 2008, nearly six times the socio-
economic toll of malaria (in terms of DALYs) in the region
[48]. Because it disproportionately affects low-income individu-
als, who are least able to protect themselves against infection and
seek and complete appropriate treatment, and has a substantially
deleterious effect on the ability of those individuals topursue edu-
cation, earn incomeand save their earnings,Chagas disease is part
of a self-propagating cycle of poverty in many endemic regions.
More recently, widespread emigration of Latin Americans,
including a large number who are infected with T. cruzi, has
resulted in an emerging public health threat in historically non-
endemic areas of the world such as the United States, Canada,
Western Europe, Japan, and Australia (Table 1) [28, 36, 71].
The total economic toll attributed to the disease each year is esti-
mated at over $7 billion USD, with more than 10% of this cost
being incurred in the United States and Canada [36, 54].
In Latin America, T. cruzi infection most often occurs via
vectorial transmission by a type of reduviid bug called a triato-
mine or ‘‘kissing bug’’. Triatomines are nocturnal feeders that
may live in a variety of environments surrounding human
dwellings, including cracks and holes in the walls, ceilings,
and ﬂoors of substandard housing structures. After taking a
blood meal, infected triatomines often excrete feces contami-
nated with T. cruzi onto their host; T. cruzi can enter the bite
wound or a nearby mucosal surface such as the conjunctiva
when the victim inadvertently rubs these parasites across their
skin [40]. Other routes of transmission include congenital,
transfusion of contaminated blood, transplantation of organs
from infected donors, ingestion of contaminated food or drinks,
and accidental exposure (e.g. laboratory accidents). Once in the
bloodstream of a mammalian host, T. cruzi is able to infect a
variety of cell types throughout the body and establish a chronic
infection.
During the acute phase of T. cruzi infection parasitemia is
often high enough that diagnosis can be made through the
microscopic examination of blood for the blood-form (trypo-
mastigote stage) of the parasite. During the chronic stage of
Chagas disease, diagnosis can be made serologically using
enzyme-linked immunosorbent assay, indirect hemagglutina-
tion, indirect immunoﬂuorescence, or immunochromatography
to test for the presence of T. cruzi-speciﬁc immunoglobulin G
(IgG). It is recommended that at least two different types of
serological tests are used to analyze each potentially infected
individual or sample, as notable heterogeneity has been
observed among the results obtained using different testing
methods, and because there is considerable risk of obtaining
false positive results with individual tests due to cross-reactivity
of anti-T. cruzi antibodies with antigens of closely related spe-
cies of trypanosomatids [19, 41, 70, 81]. Thoroughly purifying
antigenic preparations prior to analysis and selecting tests with
the greatest speciﬁcity available can reduce the risk of obtaining
false positive results with serological tests. Another potential
diagnostic tool for T. cruzi infection is polymerase chain reac-
tion (PCR) to assess the presence of T. cruzi DNA. However,
despite promising results for effective use of PCR in the diag-
nosis of T. cruzi in certain instances in which serological diag-
nosis may be especially limited, such as in neonates with low
parasitemia and in HIV co-infected patients, a combination of
Table 1. Estimated number of cases of Trypanosoma cruzi infection by country, as of 2009 [54, 55].
Region 1–999 1000–9999 10,000–99,999 100,000–999,999 >1,000,000
Central and South America Belize
Costa Rica
French Guyana
Guyana
Nicaragua
Panama
Suriname
Uruguay
Bolivia
Chile
Colombia
Ecuador
El Salvador
Guatemala
Honduras
Paraguay
Peru
Venezuela
Argentina
Brazil
North America Canada United States Mexico
Europe Austria
Croatia
Denmark
Germany
Greece
Luxembourg
Netherlands
Norway
Portugal
Romania
Sweden
Belgium
France
Italy
Switzerland
United Kingdom
Spain
Asia and Oceania Australia
Japan
Africa
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serological methods remains the preferred method of diagnosis
due to generally higher sensitivity and commercial availability,
and lower heterogeneity [19, 31, 41, 70].
After an incubation period of 5–40 days, 10–30% of
infected individuals will begin to exhibit non-speciﬁc symp-
toms of acute Chagas disease, including abdominal pain, anor-
exia, fever, lymphadenopathy, malaise, rash and localized
swelling around the site of infection [63]. The mortality rate
of acute Chagas disease is 5–10%, usually due to acute myocar-
ditis or meningoencephalitis, with the majority of deaths
occurring in young children [82]. However, the majority of
T. cruzi-infected individuals become asymptomatic carriers of
the parasite, often with low or undetectable parasitemia (though
T. cruzi-speciﬁc antibodies and DNA may remain at detectable
levels in the blood) [1, 77, 83]. After several decades in this
indeterminate disease state, during which there are no clinically
overt symptoms of organ damage or abnormal electrocardio-
graphic results, approximately 30–40% of asymptomatic carri-
ers will develop chronic Chagas disease characterized by
dilated cardiomyopathy leading to congestive heart failure,
and/or by development of gastrointestinal disorders, the two
most prominent being megacolon and megaesophagus [71].
The etiology of Chagas disease pathogenesis is complex and
not completely understood, and may involve a combination
of cellular and neuronal damage directly mediated by live
T. cruzi, as well as indirect damage caused by immune
responses to the parasite and self-antigens exposed during
infection [18, 61]. A lengthy period of parasite persistence
appears to be necessary for the induction of Chagas pathogen-
esis [18, 61]. A number of factors, including the host and par-
asite genetics, infective dose, route of transmission, number of
reinfections, and initial and late host immune response affect
the onset, severity and presentation of symptoms [5, 8, 20,
27, 38, 63].
Only two drugs, benznidazole and nifurtimox, have been
shown to be effective enough to warrant widespread use in
Chagas disease treatment. Benznidazole functions, in part, by
inducing the formation of free radicals and other metabolites
which bind to the nuclear and mitochondrial DNA of T. cruzi,
leading to lethal DNA strand breaks [69]. Nifurtimox also
exploits the parasite’s vulnerability to oxygen radicals by inhib-
iting the function of an enzyme T. cruzi requires for detoxifying
such compounds [34]. It is widely recommended that treatment
with one of these drugs be administered immediately following
conﬁrmative diagnosis to those experiencing symptoms of
acute Chagas disease. Current treatment protocols are effec-
tively curative in approximately 60% of all acute Chagas cases,
but the success rate is only 10–20% for symptomatic chronic
Chagas disease, and it remains to be proven whether anti-
trypanosomal chemotherapy provides any substantial beneﬁt
to patients experiencing the asymptomatic indeterminate state
of the disease [4, 12, 15, 23, 74]. Compared with adults,
benznidazole treatment of T. cruzi-infected children is consider-
ably more effective and better tolerated [4, 15]. In children, the
overall rate of curative therapy has been reported as 71.5% for
acute cases of Chagas disease, with >90% cure rates reported
for cases of congenital infection if treatment is given within
the ﬁrst year of life [3, 15]. The cure rate of recent chronic
Chagas disease in children (0–14 years of age) has been
reported as 57.6%; however, this represents a minority of all
chronic Chagas patients, as the majority of chronic Chagas
patients are 15–69 years of age [3, 42, 58]. It is important to
note that anti-T. cruzi treatment efﬁcacy is difﬁcult to accurately
assess due to the inherent uncertainty of determining whether
and when viable parasites have been completely eliminated
from an infected individual. Due to the lack of a reliable early
indicator of curative therapy, treatment efﬁcacy is evaluated by
the conversion of a previously positive serological test to neg-
ative, with long-term follow-up testing for a period of 10–20
years following treatment [52], Consequences of the current
inability of physicians to obtain and disseminate timely and
accurate information about treatment efﬁcacy to patients
include reluctance of patients to complete lengthy treatment
regimens and seek follow-up counseling, and impaired ability
of physicians to adequately assess and inform patients of their
long-term risk of cardiac pathology [52].
In addition to its limited efﬁcacy, treatment with benznidaz-
ole or nifurtimox poses a substantial risk of serious side effects,
including digestive intolerance, hepatitis, peripheral neuropathy,
and rash, which have been observed in 30–50% of treated indi-
viduals [36]. Use of these drugs is contraindicated during preg-
nancy and in patients with advanced kidney or liver disease,
and may be logistically or economically prohibitive to other
patient populations because a lengthy 60–90 day treatment reg-
imen is often required [36, 71]. Recent estimates place the cost
of treatment for an infected individual, depending on the level
of care provided, at $46–$7981 USD per year in Colombia and
$3000–$14,580 USD per year in Mexico [86]; the per capita
GDP in both of these countries is under $10,000 USD accord-
ing to the International Monetary Fund. These drugs are also
not widely available in all areas, and many infected individuals
in endemic countries have limited access to health care facili-
ties. Even in the United States these drugs are available only
if obtained directly from the Centers for Disease Control
(CDC) under an investigational protocol because the United
States Food and Drug Administration (FDA) has not yet
approved them for routine use in the country. For both of these
drugs to be effective, treatment for at least 60 days is required,
which compounds the burden of these health, economic, and
logistical impediments [71].
Progress against Chagas disease in endemic
regions
By some estimates, the number of people infected by T. cruzi
worldwide has been reduced by 50% or more within the past
25 years, from a peak of 15–30 million in 1990 [32, 33], to a cur-
rent total of 8–10 million [89]. After reaching a peak in the
1980s, the number of annual deaths from Chagas disease is
estimated to have dropped from 45,000 in 1990 to approxi-
mately 12,000 in recent years [32, 60]. Although variations
and inherent uncertainties in epidemiological methodology
may have resulted in certain studies greatly overestimating
the actual prevalence of T. cruzi infection, especially in earlier
years, it is clear that extensive public health initiatives in ende-
mic countries have been effective at signiﬁcantly reducing the
rate and risk of new infections.
K.M. Bonney: Parasite 2014, 21, 11 3
Control of the insect vector that transmits T. cruzi infection
has historically been the primary focus of public health pro-
grams aimed at reducing the prevalence of Chagas disease.
For the ﬁrst several decades following the identiﬁcation of
T. cruzi as the causative agent of Chagas disease there was
no speciﬁc treatment available for human infections and com-
mon methods for reducing infestation of domestic dwellings
such as the use of kerosene, cyanide gas, or ﬂame throwers
were crude and potentially destructive [33]. By the 1940s, focus
had shifted to the development of insecticides and improvement
of housing structures to limit the persistence and spread of the
vector. Because domestic animals, especially dogs, can serve as
epidemiologically important reservoirs for the parasite, efforts
to eradicate the vector were extended to domestic animal dwell-
ings [44, 59]. By the 1990s, the success of vector eradication
programs had become evident in a number of localities and
nations, largely due to the success of several large-scale
multi-national initiatives.
The most notable of these programs are the Southern Cone
Initiative (launched in 1991), the Andean Pact Initiative
(launched in 1997) and the Central America Initiative (launched
in 1997). The main objectives of these programs were to reduce
vectorial transmission by eliminating populations of domestic
vectors, to increase screening of blood donors in order to pre-
vent transmission via transfusion, and to expand maternal
screening to decrease the incidence of congenital transmission
and ensure appropriate treatment of potentially infected neo-
nates. In many regards these programs have been resoundingly
successful. By 1999, the Pan-American Health Organization
(PAHO) had declared that Triatoma infestans, the primary
domestic vector of T. cruzi in rural areas of South America,
had been effectively eliminated from human dwellings in
Brazil, Chile, Uruguay, and large portions of Argentina,
Bolivia, and Paraguay [60, 71, 78]. Efforts to eliminate
Rhodnius prolixus, widely considered to be the second most
important vector for the transmission of Chagas disease, have
been similarly effective in Guatemala, Honduras, and El
Salvador, and preliminary results indicate progress is being
made in additional areas [33]. Eradication of R. prolixus from
all of Central America is now considered feasible in the rela-
tively near future [33]. As a result of vector control, the esti-
mated number of T. cruzi-infected individuals dropped
substantially in all ten South American countries targeted by
the Southern Cone and Andean Pact Initiatives between 1980
and 2005, as well as for most of the countries targeted by the
Central America Initiative [71]. The population deemed at risk
for contracting Chagas disease also dropped markedly in the
countries targeted by these initiatives. For example, the percent
of the Chilean population deemed at risk for contracting the
infection dropped from 63% to 5% between 1980 and 2005
[71]; Venezuela experienced a decrease in infection risk from
72% to 18% during the same time period [71].
Following widely successful efforts to reduce vectorial
transmission of T. cruzi, blood transfusion became the primary
cause of infection in many areas [66]. Mandatory screening of
blood products began in many Latin American countries in
1988 [30], and by 2005 100% screening coverage had been
achieved in 12 of those countries, with two additional countries
achieving 99% coverage [60]. In Brazil, the percent of blood
donor candidates who have Chagas disease decreased tenfold
in the twenty-ﬁve years following 1980, from 4% to 0.4%
[33]. These efforts have likely resulted in the prevention of mil-
lions of new infections. However, it is notable that the lowest
rate of blood donor screening reported by a Latin American
country in the aforementioned study, 80%, was in Bolivia
[60]. This is of particular importance because Bolivia also
has the highest rate of T. cruzi infection in the world, as well
as the highest rate of seroprevalence among tested donors
[6, 60]. Subsequently, at least one study has indicated that
Bolivian immigrants in Europe are more than twice as likely as
other Latin American immigrants to be infected with T. cruzi [6].
Congenital transmission accounts for over 15,000 [67]
cases of T. cruzi infection each year, mostly in endemic regions,
justifying its selection as the third main target of the major Latin
American anti-Chagas initiatives of the 1990s. Since the late
1990s, a number of Latin American countries, including Argen-
tina, Uruguay, and Paraguay, have implemented policies to rou-
tinely screen all pregnant woman and infants serologically for
indications of T. cruzi infection. Because the risk of congenital
T. cruzi transmission may last for years after a potential mother
initially contracts the infection, and due to widespread emigra-
tion of infected individuals, congenital transmission is of con-
cern in both endemic and non-endemic areas, and in areas
where vector transmission has been interrupted or eliminated.
Due to the substantial side effects and unclear teratogenic risks
of available trypanocidal medications and a lack of other ther-
apeutic options, there is no reliable method for preventing con-
genital infection. The most effective strategy for limiting the
spread of congenital Chagas disease is widespread dissemina-
tion of available treatment to T. cruzi-infected women of
child-bearing age coupled with routine serological screening
of pregnant mothers and prompt treatment of children born to
infected mothers. Despite therapeutic limitations, extant deﬁ-
ciencies in the requisite diagnostic and clinical infrastructure,
and low rates of coverage in impoverished rural areas, there
is evidence that the rate of congenital transmission and the mor-
bidity and mortality associated with congenital transmission is
declining in a number of areas [78, 85].
The signiﬁcant decrease in new infections, hospitalizations,
loss of healthy years of life and fatalities from Chagas disease
achieved by the efforts of successful public health campaigns
has resulted in a substantial economic beneﬁt to the world,
and to Latin America in particular. Although the sum of this
economic beneﬁt is difﬁcult to measure precisely, analysis con-
ducted in the year 2000 estimated that the $420 million USD
that the Brazilian government had invested in Chagas disease
control between 1975 and 1995 had already resulted in
over $3 billion USD in beneﬁts, yielding a net return of
$7.16 USD for every dollar invested [2, 33].
The emerging threat of Chagas disease
While the prevalence of Chagas disease in Latin America
has been reduced in recent decades, the United States and a
number of non-endemic countries in Europe and the Western
Paciﬁc Region have experienced a considerable increase in
the number of T. cruzi-infected individuals. By the 1980s there
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had still been no ofﬁcial estimate of the number of
T. cruzi-infected individuals in the United States disseminated
by the CDC or WHO, and only a small number of cases had
been reported in Europe. Currently, the best estimates available
place the number of T. cruzi-infected individuals in the United
States at over 300,000 [14, 28], with an additional 80,000 resid-
ing in Europe [51, 88], and over 10,000 in other non-endemic
countries, most notably Australia, Canada, and Japan [71, 89].
These numbers may even be understating the extent of the
Chagas disease burden in countries outside of Latin America
which lack universal screening systems and whose physicians
are often poorly trained in recognizing the disease. Also, the
majority of infected individuals in non-endemic countries are
Latin American immigrants who often have disproportionately
poor access to health care, and are difﬁcult to accurately track
and assess from an epidemiological standpoint.
By any estimate, Chagas disease remains a major public
health burden today. To illustrate its seriousness, Chagas disease
has been labeled ‘‘The New HIV/AIDS of the Americas’’ by
prominent scientists due to a number of similarities in epidemi-
ology and societal impact between the two diseases [49].
Chagas disease and AIDS are both chronic conditions caused
by blood-borne pathogens that require expensive long-term
treatment, and for which there is no effective cure or preventive
vaccine. Both diseases affect large numbers of people and exact
a substantial social and economic toll. Currently, the number of
people infected with T. cruzi in Central and South America is
estimated to be over ﬁve times the number of people infected
with HIV in the same region; however, the global number of
HIV infections is higher than the number of T. cruzi-infected
individuals [71]. Both diseases pose infection risks to recipients
of blood transfusion and organ donation and to children of
untreated infected mothers. Moreover, both diseases are highly
stigmatized and disproportionately affect individuals living in
poverty and least able to access the medical and social support
necessary for maintaining the highest possible quality of life.
These striking comparisons may prove to be effective at
increasing awareness of the seriousness of Chagas disease;
however, substantial differences between the infectivity, mortal-
ity rate and treatment of the two diseases impose considerable
limitations on their comparison. Whereas AIDS is almost
always fatal and control of HIV infection requires lifelong anti-
retroviral treatment, only 20–30% of people infected with
Chagas disease will develop potentially fatal cardiomyopathy
in their lifetime, and T. cruzi infection is relatively controllable
with short-term treatment compared with HIV.
One of the most noteworthy recent developments in broad-
ening understanding of Chagas disease regards not what occurs
during T. cruzi infection, but rather where T. cruzi infection
occurs. In addition to acknowledging the rapidly increasing
number of T. cruzi-infected individuals currently residing in
non-endemic countries, it is important to note that not all cases
of T. cruzi infection that occur outside of Latin America involve
Latin American immigrants who were infected in their coun-
tries of origin. One cause of newly acquired T. cruzi infections
in countries such as the United States, Spain, Switzerland, and,
most recently, Japan is congenital transmission [24, 50, 51, 73].
Although the precise number of congenital Chagas cases in
non-endemic countries is unknown [21], it is estimated that
40,000 pregnant women and 2000 newborns are infected with
T. cruzi in North America (Canada, Mexico, and the United
States) alone. Because T. cruzi-infected neonates are often
asymptomatic or exhibit non-speciﬁc clinical signs, and obste-
trician-gynecologists in non-endemic countries often have lim-
ited awareness of Chagas disease and may be less likely to
provide the prompt diagnosis and treatment that is crucial for
preventing disease progression, congenital transmission is a
serious concern that warrants increased attention [24]. Adoption
of potentially infected children from endemic regions as well as
travel to endemic regions by foreigners may also result
in a number of cases of T. cruzi infection in non-endemic
countries [28].
There are several additional ways that individuals living
outside of Latin America may acquire T. cruzi infection without
having lived in or being born to a mother from an endemic
region: receipt of contaminated blood products or organs, vec-
torial transmission, and laboratory accidents. Of these, transmis-
sion through blood transfusion or organ transplantation has
resulted in the highest number of T. cruzi infections in non-
endemic countries, with approximately 20 infections having
been recorded in Canada, Spain, and the United States; most
or all of these involving donors originating from endemic coun-
tries [11, 13, 88]. The United States and France did not begin
screening blood donors for the presence of T. cruzi until
2007, and many non-endemic countries either did not start
screening for the parasite until even more recently, or still do
not engage in widespread screening. As of 2014, Japan still
has not implemented routine laboratory-based screening of
donated blood for the presence of T. cruzi, and the country also
does not customarily screen pregnant mothers for T. cruzi infec-
tion, relying instead on a questionnaire to determine whether
self-reported risk factors warrant individualized testing [50].
As of January 2014, at least 1900 seropositive donors have
been reported in the United States since testing began in
2007, according to the American Association of Blood Banks
website. The proportion of US blood donors testing positive
for T. cruzi is highest in areas with large numbers of Latin
American immigrants, such as Los Angeles and Miami, where
the seropositive rates have been reported as 1 in 7500 and 1 in
9000, respectively [56].
As of 2011, only 7% of the 58 organ procurement organi-
zations active in the United States routinely screened all organ
donors serologically for T. cruzi, with an additional 12%
employing selective screening of high-risk donors [79]. In
2008, 17 donor organs being considered for transplantation into
recipients were discarded following a positive test for T. cruzi
[79]. Because T. cruzi-infected individuals may remain asymp-
tomatic for decades before developing life-threatening health
problems, it is conceivable that additional people have already
been infected with the parasite following the receipt of a blood
or organ donation and are unaware of their infection status.
Of the 65 cases of T. cruzi infection known to have been
acquired via laboratory accidents, at least 11 occurred in the
United States or Europe [46]. Although not a similar threat out-
side of North America, at least seven cases of vectorial trans-
mission of T. cruzi have been veriﬁed in the United States
since 1955 [13, 22, 35, 47, 65, 76, 90]. The range of triatomine
bugs capable of transmitting T. cruzi extends across twenty-six
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states in the southern half of the country, though infestation of
domestic dwellings by triatomine bugs is rare and usually only
occurs under atypical conditions, such as following severe
droughts [10, 13, 72, 75].
Oral transmission of T. cruzi, which usually occurs due to
ingestion of fresh sugar cane or ac¸aı´ berry juice made from
plants harboring infected triatomine bugs, is now the primary
cause of T. cruzi infection in some areas of Latin America, such
as the Amazonian region of Brazil [80]. Oral transmission has
resulted in over 1000 cases of acute Chagas disease in Latin
America since the year 2000 [80]. This mode of transmission
is considered an emerging threat because outbreaks are spo-
radic, difﬁcult to predict, and have shown no signs of declining
in frequency or severity. The main threat that this route poses to
individuals in non-endemic countries is the risk to tourists trav-
eling to areas where consumption of contaminated beverages or
foods is most likely.
The future of Chagas disease
Development of an effective vaccine or other new and
improved therapies is a crucial, and perhaps the most antici-
pated and important next step in the ﬁght against Chagas dis-
ease [53, 55, 68]. A number of groups are currently in the
advanced stages of developing novel therapies, including both
DNA- and antigen-based vaccines [36, 37, 43, 62, 68, 87,
91] as well as other anti-trypanosomal drugs including chemical
agents that competitively inhibit the function of critical T. cruzi
enzymes [16]. Preliminary data demonstrating the efﬁcacy of
several of these candidate drugs has been promising, and pro-
gress into clinical trials for at least one candidate vaccine which
targets two T. cruzi antigens (Tc24 and TSA-1) and includes a
TLR4 agonist is likely to occur within the next ﬁve years [37].
Beneﬁts of a potential vaccine for T. cruzi compared with the
use of standard chemotherapeutic agents include reduced toxic-
ity, allowing for expanded use in chronic patients and patients
with comorbidities, potential use during pregnancy to prevent
congenital transmission, increased protection against cardiac
complications, and removal of treatment barriers asso-
ciated with the effort and cost of administering repeated
drug treatments. Due to the controversial proposition that
T. cruzi-induced autoimmunity may play a role in the cardiac
pathogenesis of human Chagas disease, it is recommended,
even by experts who agree that protective anti-T. cruzi immu-
nity can be promoted by vaccines without the risk of eliciting
pathogenic autoimmunity, that vaccine candidates continue to
be monitored and tested for this potential risk [36]. In the
absence of a rapidly effective cure, work must continue on
the development of improved treatments and prognostic indica-
tors for sustained organ damage in chronic Chagas patients,
including expanding insight into genetic factors that may inﬂu-
ence susceptibility to disease progression and reparative stem
cell therapies to ameliorate cardiac damage [8, 29, 38].
Continued progress toward limiting the spread of Chagas
disease also requires sustained efforts at widespread vector con-
trol [60], reﬁnement of infection and disease risk assessment
[38, 64], improvement in the quality of diagnostic tests for
screening individuals and the blood supply [1], increased
availability of existing therapies and diagnostic tests [57],
and expansion of surveillance programs in endemic
regions [27, 60]. The Amazonian region of Brazil is of partic-
ular importance for surveillance efforts due to the high rate of
habitat conversion of previously uninhabited wilderness into
dwellings and farmland, creating potential points of contact
between T. cruzi and humans [27, 60]. Also, oral transmission
of T. cruzi is more prevalent here than anywhere else in the
world, and will likely continue to cause a signiﬁcant number
of new infections for many years to come [78, 80]. In addition
to maintaining and expanding the aforementioned efforts, ende-
mic countries must continue providing care for the approxi-
mately 10 million people already infected with T. cruzi,
which will include hospitalizations and other long-term and
expensive treatments for many thousands of individuals.
Another important concern in the ongoing effort to control
Chagas disease is maintaining a high enough level of political
priority to promote and fund surveillance and research at the
levels necessary to prevent lapses or regression in the success
of public health programs [27, 45, 60]. As stated by Dias
et al. [33], ‘‘the greatest risk to the current successful trend in
Chagas disease control comes, in a sense, from the success that
has been achieved.’’ To elaborate, knowledge of the widespread
reduction in the prevalence and risk of T. cruzi infection that has
already been achieved may, over time, result in a loss of interest
in and commitment to providing and improving surveillance
and research and treatment strategies, or a large-scale shifting
of resources to more emergent issues. Development of compla-
cency or a lackadaisical attitude toward Chagas disease would
carry the risk of allowing a progressive reestablishment of
T. cruzi transmission and losing the ability to effectively deal
with future outbreaks. Therefore, it is important to maintain
robust, centralized public health programs to track and treat
T. cruzi transmission, as well as continue to educate the public
about the risks of and preventive strategies for the disease.
Additionally, efforts to control the spread of Chagas disease
must include increased emphasis on monitoring and controlling
globalization of the disease, including the emerging threat of
Chagas disease in Europe, Japan, Australia, and the United
States and the need for increased surveillance in those areas
[6, 9, 13, 27, 28, 39, 49, 60]. Unlike in most regions of Latin
America, the number of T. cruzi-infected individuals is rising
considerably in non-endemic countries such as the United
States, and over 10% of the global healthcare burden related
to Chagas disease already originates outside Latin America
[54]. Also unlike endemic countries, health care professionals
and the public in historically non-endemic countries lack a long
history of training and awareness in how to prevent, detect, and
treat the disease. In areas where Chagas disease is newly emerg-
ing as a major public health concern, as in endemic countries, a
crucial part of any successful campaign to limit the spread of
T. cruzi infection is education. It is recommended that training
in practical methods for identifying and protecting against the
vector and for recognizing and seeking treatment for symptoms
of potential infection be widely disseminated to primary school
educators and community health advocates, in addition to phy-
sicians and other health care providers [25]. Increasing aware-
ness of Chagas disease among children is also important
since many infections occur during childhood, and because it
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is the youngest generation that will become the future research-
ers, health care providers and public policy-makers tasked with
the challenge of breaking the self-propagating cycle of a disease
that disproportionately affects the poor and further contributes
to poverty due to loss of productivity and healthcare costs
[17, 25, 78].
Conclusion
There is a growing consensus that Chagas disease, no
longer conﬁned to poor rural areas of Latin America, is now
a worldwide public health concern and will remain so for the
foreseeable future. However, after decades of improvements
in surveillance, treatment, and vector-eradication strategies,
effective elimination of the disease in the near future is becom-
ing an increasingly attainable goal. Future success in the ﬁght
against Chagas disease is dependent upon effective manage-
ment of newly emerging infectious foci, maintenance of high
levels of public awareness and government interest in control-
ling the disease, and continued improvements in diagnostic,
therapeutic, and surveillance tools. Lessons learned from the
past 100 years of combating T. cruzi infection must continually
be applied and improved upon in order for the next 100 years to
yield continued progress against and possibly even eradication
of Chagas disease.
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